Myeloablative chemotherapy in testicular cancer patient Case report

Article Sidebar

PDF


Published: Mar 24, 2021
DOI: https://doi.org/10.24292/01.OR.121030321
Keywords:
chemotherapy, autologous hematopoietic stem cell transplantation, non-seminoma

Main Article Content

Karolina Furgała
Collegium Medicum, University of Warmia and Mazury
Zuzanna Smuniewska
Collegium Medicum, University of Warmia and Mazury
Dawid Sigorski
1. Department of Oncology, Collegium Medicum, University of Warmia and Mazury. 2. Clinical Department of Oncology and Immuno-Oncology, Warmian-Masurian Cancer Center of The Ministry of The Interior and Administration’s Hospital, Olsztyn, Poland
Maciej Michalak
1. Department of Oncology, Collegium Medicum, University of Warmia and Mazury. 2. Department of Radiology, Warmian-Masurian Cancer Center of The Ministry of The Interior and Administration’s Hospital, Olsztyn, Poland
Lubomir Bodnar
1. Department of Oncology, Collegium Medicum, University of Warmia and Mazury. 2. Clinical Department of Oncology and Immuno-Oncology, Warmian-Masurian Cancer Center of The Ministry of The Interior and Administration’s Hospital, Olsztyn, Poland

Abstract

Chemotherapy is the standard treatment for metastatic testicular cancers. The autologous hematopoietic stem cell transplantation is a salvage option for relapsed patients. The paper presents a case of a 20-year-old patient with stage IIIC non-seminoma treated with BEP chemotherapy and autologous transplantation of stem cells, which allowed to achieve durable remission.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Furgała K, Smuniewska Z, Sigorski D, Michalak M, Bodnar L. Myeloablative chemotherapy in testicular cancer patient. OncoReview [Internet]. 2021Mar.24 [cited 2024Dec.23];11(1(41):19-1. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/1195
Issue
Vol 11 No 1(41) (2021)
Section
HEMATO-ONCOLOGY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Mead GM, Stenning SP; Clinical Oncology Editorial. The International Germ Cell Consensus Classification: A New Prognostic Factor-Based Staging Classification for Metastatic Germ Cell Tumours. Clin Oncol (R Coll Radiol). 1997; 9(4): 207-9.
2. Einhorn LH, Williams SD, Chamness A et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007; 357: 340-8.
3. McHugh DJ, Feldman DR. Conventional-dose versus high-dose chemotherapy for relapsed germ cell tumors. Adv Urol. 2018; 2018:7272541.
4. Lorch A, Bascoul-Mollevi C, Kramar A et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011; 29: 2178-84.
5. Feldman DR, Sheinfeld J, Bajorin DF et al. TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis. J Clin Oncol. 2010; 28: 1706-13.